NKGN Pangali EV/EBITDA NKGen

The price history on GURU.Markets shows that NKGen Biotech, Inc. (NKGN) has an EV/EBITDA multiple of . NKGen Biotech, Inc. (NKGN) utilizes automated sterile complexes to scale drug production. The business develops innovative methods to combat dementia and tremors, leveraging protected patents. Meanwhile, the lack of sales is leading to a gradual depletion of cash reserves due to medical trial expenses.

To assess the financial stability of NKGen Biotech, Inc. (NKGN), verifying the business's ability to service its obligations is critical. This indicator correlates the total enterprise value of the company with its operating income, determining the payback period for all assets inclusive of net debt. By analyzing the EV/EBITDA ratio alongside the capital structure, an investor can identify the bankruptcy risk of the biotech firm amid losses and high uncertainty surrounding clinical trials.